Table 2.
Remission-SZ group (n = 28) |
TRS group (n = 30) |
ASD group (n = 28) |
Analysis |
|||||
---|---|---|---|---|---|---|---|---|
ANOVA (F-value) |
ANOVA (p-value) |
Post-hoc (p-value) |
||||||
Rem vs. TRS | Rem vs. ASD | TRS vs. ASD | ||||||
Autistic traits: | ||||||||
AQ [range 0–50: cutoff < 33] | 24.32 [7.19] | 27.67 [7.75] | 33.29[6.17] | 11.47 | <0.001 | 0.177 | <0.001 | 0.009 |
ASQa [range 0–34: cutoff < 13] | 6.83 [4.64] | 9.09 [5.92] | 11.15 [5.57] | 3.90 | 0.025 | 0.338 | 0.018 | 0.381 |
PARS TR-infancya [range 0–68: cutoff < 9] | 4.10 [3.23] | 6.23 [4.07] | 13.70 [5.72] | 27.33 | <0.001 | 0.287 | <0.001 | <0.001 |
PARS TR-presenta [range 0–66: cutoff < 20] | 9.25 [5.66] | 15.86 [6.32] | 20.87 [7.01] | 17.33 | <0.001 | 0.004 | <0.001 | 0.029 |
MCCB (T score): | ||||||||
Speed of process | 42.00 [8.63] | 28.53 [13.26] | 46.14[13.70] | 16.89 | <0.001 | <0.001 | 0.411 | <0.001 |
Attention/vigilance | 47.43 [11.49] | 35.67 [10.97] | 51.46 [9.07] | 17.61 | <0.001 | <0.001 | 0.331 | <0.001 |
Working memory | 42.86 [10.66] | 30.90 [14.45] | 44.32 [11.27] | 10.50 | <0.001 | 0.001 | 0.896 | <0.001 |
Verbal learning | 35.50 [8.50] | 30.70 [5.92] | 46.61 [10.48] | 26.74 | <0.001 | 0.043 | 0.001 | <0.001 |
Visual learning | 49.04 [8.57] | 39.07 [14.26] | 50.39 [7.25] | 10.00 | <0.001 | 0.006 | 0.799 | <0.001 |
Problem solving | 53.29 [11.64] | 43.77 [10.60] | 53.11 [9.93] | 7.53 | 0.001 | 0.003 | 0.998 | 0.004 |
Social cognition (MSCEIT) | 36.07 [11.73] | 27.37 [12.85] | 37.11 [11.77] | 5.68 | 0.005 | 0.021 | 0.945 | 0.008 |
False-belief tasks (5 tasks) [range 0–5] | 4.29 [0.94] | 3.50 [0.86] | 3.75 [1.08] | 5.02 | 0.009 | 0.007 | 0.098 | 0.584 |
Data are mean [SD].
ANOVA: analysis of variance, AQ: Autism-Spectrum Quotient, ASD: autism spectrum disorder, ASQ: Autism Screening Questionnaire, MCCB: MATRICS Consensus Cognitive Battery, Rem: remission schizophrenia, PARS TR: Pervasive Developmental Disorder Assessment Rating Scales Text Revision., SZ: schizophrenia, TRS: treatment-resistant schizophrenia.
PARS-TR (infancy and present data) and ASQ were available from 65 patients (RemSZ, n = 20; TRS, n = 22; ASD, n = 23) and 72 patients (RemSZ, n = 23; TRS, n = 23; ASD, n = 26), respectively.